Kornimate/medical-research-clean huggingface dataset:
multicenter assessment of the pancreas in type 1 diabetes

Conditions: Diabetes Mellitus

Summary: the overall goal of this research is to develop and validate standard operating procedures (sop) to assess the human pancreas in individuals with type 1 diabetes (t1d) and other forms of diabetes using advanced, quantitative magnetic resonance imaging (mri) approaches.

this research applies magnetic resonance imaging (mri) techniques to study the pancreas of individuals with type 1 diabetes (t1d) and other forms of diabetes. recent studies have demonstrated reduced pancreatic volume is present within months of t1d diagnosis in children, adolescents, and adults, and in non-diabetic individuals expressing islet autoantibodies that portend the development of t1d. as the pancreatic beta cells constitute only 1-2% of the pancreas, the degree of reduction in pancreas volume at disease onset suggests exocrine involvement, challenging the established paradigm of t1d being solely a disease of the endocrine pancreas. these unexpected findings raise fundamental questions that challenge our understanding of t1d pathogenesis. these changes in pancreatic volume and size before and soon after onset of t1d, as detected by mri, appear to be a marker of the t1d pathogenic disease process. there is an urgent need to determine whether similar observations can be obtained at different centers using different mri platforms. discovery of unknown changes may lead to new ways to treat disease. the mri techniques may also be useful for following how t1d is progressing in different people, determining whether new drugs are effective, and ultimately detecting t1d in people earlier than currently possible.

Eligibility criteria:
inclusion criteria: * subjects at least 8 years of age * subjects with t1d must be imaged within 100 days of their date of diagnosis * subjects must be able to read and provide assent/informed written consent exclusion criteria: * subjects with pancreatitis, cystic fibrosis, pancreatic adenocarcinoma, or neuroendocrine tumors * subjects who have any type of bioimplant activated by mechanical, electronic, or magnetic means because such devices may be displaced or malfunction * subjects who have any type of ferromagnetic bioimplant that could potentially be displaced * subjects who are pregnant or breast-feeding. urine pregnancy test will be performed on women of child bearing potential who are not practicing appropriate contraception measures or menstruating. * subjects who exhibit significant anxiety and/or claustrophobia * subjects incapable of giving assent/informed written consent * for controls: subjects who have first degree relatives with t1d
long-term use of proton pump inhibitors may cause vitamin b12 deficiency in the institutionalized elderly

Conditions: Vitamin B12 Deficiency

Summary: this study was designed to determine whether elderly residents of long term care facilitated who had been taking proton pump inhibitors (ppi) for more than 12 months were more likely to have vitamin b12 deficiency than residents not taking ppi, and whether cyanocobalamin nasal spray improved these subjects' vitamin b12 status.

subjects had serum creatinine \<1.8 mg/dl, no diagnosis of severe megaloblastic or pernicious anemia, and had not been taking vitamin b12 supplements. at baseline, serum vitamin b12 and methylmalonic acid (mma) concentrations of 34 subjects from the ppi group were compared with those of the non-ppi group. the ppi group (n=13) was treated with cyanocobalamin nasal spray for eight weeks, and post-treatment vitamin b12 and mma concentrations were compared with baseline concentrations.

Eligibility criteria:
inclusion criteria: * age 60-89 years * ppi use for \>12 months (ppi group) * no ppi use for 30 days prior to arm 1 * long term care resident exclusion criteria: * pernicious anemia * severe megaloblastic anemia * free-living * serum creatinine \> 1.8 mg/dl

Keywords: vitamin b12 deficiency cyanocobalamin deficiency proton pump inhibitors omeprazole
intensive glycemic control for congestive heart failure exacerbation

Conditions: Congestive Heart Failure; Diabetes Mellitus

Summary: patients with heart failure often have high blood sugar (glucose).

patients with heart failure often have high blood sugar. high glucose contributes to severe hospital complications and even death. studies suggest that heart failure patients who have high glucose or diabetes do not live as long as patients with normal glucose. in this study, we will determine whether normalizing blood sugars using intravenous insulin short-term will improve outcomes in patients hospitalized for congestive heart failure. we enrolled patients with severe heart failure and randomly assigned them into 2 groups. we used intravenous (given through the vein) insulin to lower blood sugar levels in group 1, and insulin injections in group 2. we determined whether intravenous insulin improved hospital length of stay, rates of readmission, inflammatory markers, and cardiovascular tests that predict mortality in patients with heart failure.

Eligibility criteria:
inclusion criteria: * age 18 and above * admitted (less than 48 hours) to the osu ross heart hospital with worsening heart failure * hyperglycemia or diabetes. hyperglycemia is defined as blood glucose greater than 150 mg/dl on at least 2 occasions separated by at least 4 hours apart, insulin use, or hba1c \>6.5%. exclusion criteria: * type 1 diabetes * receiving comfort care measures only * hospital stay expected to be less than 2 days * pregnancy * prisoners * participation in the study on prior hospitalizations * acute myocardial infarction within 3 months * end stage renal or liver disease

Keywords: heart failure hyperglycemia hospital diabetes mellitus
pain modulatory profiles in stretching

Conditions: Healthy

Summary: the purpose of this study is to characterize immediate changes in pain sensitivity during stretching to the point of pain, stretching in a pain free range, and a cold water immersion task. participants will attend three sessions during which they will undergo pain sensitivity assessment and complete the assigned intervention.


Eligibility criteria:
inclusion criteria: * pain free exclusion criteria: * non-english speaking * regular use of prescription pain medications * current or history of chronic pain condition * currently taking blood-thinning medication * any blood clotting disorder, such as hemophilia * systemic medical condition known to affect sensation, such as uncontrolled diabetes or neurological conditions * any contraindication to the application of ice, such as: uncontrolled hypertension, cold urticaria, cryoglobulinemia, paroxysmal cold hemoglobinuria, circulatory compromise * not physically ready to exercise without a medical exam as indicated by the physical activity readiness questionnaire plus (par-q+) * surgery, injury, or fracture to the neck or upper extremity within the past 6 months * unable to perform the stretch * unable to attend all three sessions
surgical treatment of injuries and consequences of the acetabulum

Conditions: Acetabular Fracture

Summary: the aim of the program is to develop technologies for the diagnosis and treatment of injuries and consequences of the pelvis. purpose: to improve the technique of surgical treatment of acetabular fractures.

tasks: implementation of low-traumatic access to the acetabulum; introduction of a new implant for osteosynthesis of complex acetabular fractures into clinical practice; мathematical modeling of fixation of the acetabulum with a new implant; рublication of the results of the work carried out the relevance of the use of new implants in orthopedics is due to the problem of adaptation of implants in the body, especially with poor quality of bone tissue. currently, work is underway to improve the materials and shapes of implants, new alloys are being studied, polymer implants are being introduced, but the problem of their integration into bones remains. a promising direction in orthopedics is the creation of implants as close as possible in their morphological shape and elasto-strength properties to human bone. but the creation of an absolute copy of the bone structure from a metal alloy leads to a weakening of its strength and loss of fixation stability, and subsequent lysis of the adjacent bone tissue. all this indicates the need for further search for new, perhaps more promising and effective ways to solve this problem.

Eligibility criteria:
inclusion criteria: * patients over 18 years of age * patients with acetabular fractures undergoing surgery * acetabular fractures according to the classification of judet and letournel exclusion criteria: * patients under 18 years of age * posterior wall fracture according to the classification of judet and letournel

Keywords: acetabulum osteosynthesis stoppa approach fracture
a study of bio-11006 in the treatment of advanced non-small cell lung cancer

Conditions: Non Small Cell Lung Cancer Stage IIIB

Summary: this phase 2 is a randomized study in advanced non-small cell lung cancer patients to evaluate safety and efficacy of aerosolized bio-11006 in conjunction with chemotherapy.

this randomized, open label, multicenter phase 2 study is to evaluate safety and efficacy of bio-11006 in stage iiib non small cell lung cancer (nsclc) patients who are not candidates for curative surgery, radiation, or immunotherapy and who are also receiving pemetrexed and carboplatin as standard of care (soc). this study will be conducted at ten clinical centers in india under an ind from us-fda and an ind from indian fda. this is a parallel 2- arm study in which a total of 60 patients will be randomized. one arm of 30 subjects will receive aerosolized 125mg bio-11006 bid using pari eflow nebulizer in conjunction with soc chemotherapy (pemetrexed plus carboplatin). a second arm of 30 subjects will receive only soc chemotherapy (pemetrexed plus carboplatin). the treatment period will be three months and nine months survival follow up period (every three months). primary efficacy endpoint will be progression-free survival (pfs) in patients who receive bio-11006 plus soc compared to those who receive soc alone. the secondary efficacy endpoints will include: a. response rate at three months (4 cycles) per recist v1.1; (b) overall survival; and (c) patient body weight maintenance.

Eligibility criteria:
inclusion criteria: 1. patients who are physically able to self administer drug by nebulizer; 2. measurable disease per recist version 1.1; 3. female patients of child bearing age must have a negative pregnancy test; 4. ecog 0-2; 5. written informed consent; exclusion criteria: 1. candidates for curative surgery and/or radiation therapy; 2. baseline anc\<2000 cells/mm cube; platelet count \<100,000 cells/mm cube 3. creatinine clearance \<45 ml/min; 4. billirubin \>2 x the upper limit of normal 5. known history of hiv, hepatitis b, hepatitis c or tuberculosis; 6. current pneumonia or idiopathic pulmonary fibrosis; 7. hypersensitivity to test drug, pemetrexed, or carboplatin.

Keywords: lung cancer non small cell metastasis
counseling intervention in hereditary hemorrhagic telangiectasia in the covid era.

Conditions: Hereditary Hemorrhagic Telangiectasia

Summary: the goal of this interventional study is to determine the incidence of depression, anxiety, sleep disturbances and resilience in a sample of subjects affected by hereditary hemorrhagic telangiectasia. the study is declined through the evaluation of some outcome parameters at the time of enrollment (t0), during the counseling intervention (t1 and t2) and at the end (t3) of the subjects who will have carried out an individual counseling intervention.


Eligibility criteria:
inclusion criteria: recruited subjects have a diagnosis of hereditary hemorrhagic telangiectasia and are 18 years of age or older. exclusion criteria: previous or current intellectual disability and a diagnosis of psychiatric disorders in accordance with the diagnostic and statistical manual of mental disorders, dsm-5.
monoclonal antibody therapy in treating patients with recurrent gliomas

Conditions: Brain and Central Nervous System Tumors

Summary: rationale: monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. purpose: phase i trial to determine the effectiveness of monoclonal antibody in treating patients with recurrent gliomas.

objectives: i. assess the toxic effects of intracystic administration of iodine-131-labeled anti-tenascin monoclonal antibody 81c6. ii. identify any objective therapeutic responses to this treatment in patients with recurrent cystic anaplastic gliomas. outline: radioimmunotherapy. iodine-131-labeled anti-tenascin monoclonal antibody 81c6, 131i-81c6. projected accrual: three to six patients will be entered at each dose studied.

Eligibility criteria:
disease characteristics: histologically confirmed supratentorial anaplastic glioma with a recurrent cyst requiring aspiration for symptom control measurable cystic lesion confirmed by contrast-enhanced ct or mri at least 3 months since radiotherapy to site of measurable disease unless unequivocal evidence of tumor progression neoplastic cell reactivity with tenascin demonstrated by immunohistology with either a polyclonal rabbit antibody or a monoclonal murine antibody patient characteristics: age: 3 and over performance status: karnofsky 50-100% hematopoietic: absolute neutrophil count greater than 1,000/mm3 platelet count greater than 100,000/mm3 hepatic: bilirubin less than 1.5 mg/dl ast less than 1.5 times normal alkaline phosphatase less than 1.5 times normal renal: creatinine less than 1.2 mg/dl other: negative pregnancy test effective contraception required of fertile women prior concurrent therapy: biologic therapy: not specified chemotherapy: at least 6 weeks since antineoplastic chemotherapy unless unequivocal evidence of tumor progression endocrine therapy: corticosteroids allowed if at lowest possible dose and dose stable for at least 10 days prior to entry radiotherapy: see disease characteristics surgery: not specified

Keywords: childhood supratentorial ependymoma recurrent childhood brain tumor recurrent adult brain tumor adult glioblastoma adult anaplastic astrocytoma adult myxopapillary ependymoma adult anaplastic ependymoma adult anaplastic oligodendroglioma adult mixed glioma adult ependymoblastoma recurrent childhood cerebral astrocytoma recurrent childhood ependymoma adult giant cell glioblastoma adult gliosarcoma
study of the blood and skin immunological profile of patients with recessive dystrophic epidermolysis bullosa: in vivo analysis and the impact of placental stem cells in vitro

Conditions: Epidermolysis Bullosa Dystrophica

Summary: patients with recessive dystrophic epidermolysis bullosa (rdeb) suffer from acute and chronic post-bullous wounds along with impaired skin healing. these issues are attributed not only to mucocutaneous fragility and abnormal healing directly related to quantitative and/or qualitative constitutional abnormalities of collagen vii but also to a contingent cutaneous and systemic inflammatory component. this inflammatory aspect contributes to the perpetuation of skin lesions and delayed healing. our primary objective is to define the systemic immunological/inflammatory signature of patients with rdeb with an aim to develop a strategy that involves using stem cells with high immunomodulatory/anti-inflammatory capacity such as allogeneic placental stem cells (wj-mscs and trophoblasts).


Eligibility criteria:
inclusion criteria: ebdr patients : * patients aged 18 to 80 years old * clinically, histologically, and/or genetically confirmed intermediate, reversed or generalized, moderate to severe ebdr healthy controls : * adults aged 18 to 80 years old * pbmc healthy donors: subjects who have donated blood to the efs according to the indication criteria who have consented to the use of their samples for research purposes. * healthy skin biopsy donors: subjects undergoing abdominoplasty scheduled in plastic surgery and who have given their consent for the collection of a skin biopsy from post-operative abdominoplasty skin remnants. * healthy donors of bandages soiled with exudates from cutaneous wounds: subject consulting a plastic surgery department as part of their usual post-operative follow-up, who have given their consent for the collection of one of their dressings during their usual during their usual renewal. for all subjects : * free, informed, written consent, signed by the person and the investigator no later than the day of inclusion and before any examination carried out as part of the study. * person affiliated or benefiting from a social security scheme exclusion criteria: ebdr patients : * ebh with no definite diagnosis or other than ebdr intermediate, reversed or generalized * systemic anti-inflammatory or immunosuppressive therapy for less than one month * refusal of skin biopsy healthy controls : * acute or chronic systemic or cutaneous inflammatory disease at the time of sampling * current immunosuppressive anti-inflammatory treatment in the month prior to sampling for all subjects: * persons under guardianship or curatorship, or deprived of their liberty by judicial or administrative decision * patients receiving state medical aid * pregnant or breast-feeding women
can genetics predict treatment response to a computerized self-help program for depression?

Conditions: Major Depressive Disorder; Mood Disorders

Summary: the goal of this project is to determine whether genetic information can be used to predict response to an internet-based treatment of depression. several studies now indicate that completing an internet-based treatment for depression, called deprexis, can significantly improve symptoms of depression. however, not everyone improves. the purpose of this study is to determine whether genetic profile can predict who is likely to improve.


Eligibility criteria:
inclusion criteria: * english-speaking * have reliable access to the internet (i.e., dialup or broadband access) * be willing to donate saliva for dna research * have a current symptoms of depression * be stable on medication and/or therapy (i.e. no changes within 2 weeks of study entry) exclusion criteria: * any diagnosis of a psychotic or bipolar disorder * meeting for alcohol/drug dependence in the past year * having current suicidal risk warranting crisis intervention

Keywords: mood disorders depression genetics treatment response treatment study
evaluation of a new technology for the treatment of bladder leakage in women

Conditions: Urinary Incontinence; Urinary Incontinence, Stress; Urinary Incontinence, Urge

Summary: evaluation of a new technology for the treatment of bladder leakage in women. the objective is to compare quality of life and other incontinence associated outcomes between women receiving routine general practitioner (gp) prescribed care for urinary incontinence compared with those prescribed the electrical stimulation device.

this united kingdom study will comprise a single blind, primary care, post-market evaluation of a novel neuromuscular electrical stimulation treatment for urinary incontinence . women with gp determined urinary incontinence (urgency, stress or mixed) will be randomised into one of two groups (intervention or control). the control group will receive routine care via their gp practice. the intervention group will receive the electrical stimulation device. treatment will last for 12 weeks with a quality of life (qol) primary end point immediately post treatment with a second phase to explore the impact of a further 12 weeks maintenance programme in the intervention group compared to routine care. there will be a further two year follow-up assessment.

Eligibility criteria:
inclusion criteria: * women * aged between 18 and 65 * gp determined urinary incontinence exclusion criteria: * abnormal abdominal mass * clinical history of urinary retention problems * severe atrophic vaginitis, vaginal infection, vaginal lesion, severe urogenital prolapse at the level of the vaginal introitus or any other pathology of the vagina or labia * pregnancy or given birth within the last three months * implanted pacemaker * recent pelvic surgery (within the last 12 months) * recent haemorrhage, haematoma and/or tissue damage to the vagina * undergoing any active therapy or review appointments for pelvic malignancy * current urinary tract infection confirmed by urinary dip stick test on initial visit (can be included following a subsequent clear urinary dipstick test) * manual dexterity insufficient to place the electrical stimulation device in the vagina * presence of a severe neurological conditions such as multiple sclerosis, motor neuron disease or parkinson's disease * multiple co-morbidities to the extent that the activities involved in the pad test (i.e. stair climbing) cannot be completed * insufficient cognitive ability to provide informed consent and/or participate in the study * unwillingness to participate in the study

Keywords: neuromuscular electrical stimulation incontinence
nutrition and resistance training in head and neck cancer

Conditions: Head and Neck Cancer

Summary: to test the effects of nutrition versus nutrition with resistance exercise on muscle mass loss, fatigue and outcomes of concurrent chemo radiation.


Eligibility criteria:
inclusion criteria: * stage 3 or 4 hnc exclusion criteria: * previous cancer
phase i clinical trial to assess safety of uv phototherapy for the prevention of gvhd post allogeneic sct

Conditions: Allogeneic Transplantation (Non T-cell Depleted)

Summary: the primary goal of thos study is to assess safety of ultraviolet (uv) phototherapy for the prevention of graft versus host disease after allogeneic stem cell transplantation (phase i - clinical trial). following allogeneic bmt, patients will be placed on standard gvhd preventive therapy (cyclosporine). secondary goals - * monitoring immune system recovery * the influence of stem cells origin on therapy and/orgvhd prevention * the influence of uv-c treatment on survival clinical data and samples will be collected, during uv-c therapy, 100 days after discharge \& 6 months after discharge - to examine the long-term effect of uv-c treatment on the patient's gvhd status.

treatment will be given with a portable, easy to operate device named "eumatron". this device contains a uv- lamp. 250 cc of blood from a peripheric vein is going through the device into a bottle with low dose heparin and returning to patient's body. procedure takes \~20 minutes.

Eligibility criteria:
inclusion criteria: * patients post non t cell depleted allogeneic stem cell transplantation exclusion criteria: * morbidity unrelated to gvhd * patients in an hemodynamic unstable condition * acute uncontrolled bleeding * patients undergoing dialysis

Keywords: allogeneic bone marrow transplantation non-t-cell depleted uv-c gvhd